πŸ₯ HealthTechOn TimeπŸ“‹ Fixed Price

HealthTech NHS Genomics England Rare Disease Data Platform

UK6 min readUpdated June 2026
Region
UK
Contract
Fixed Price
Tech Stack
12 Technologies
IP
100% transferred

Project Overview

A genomics data company partnering with NHS Genomics England needed to build a rare disease variant interpreta...

Technology Stack

ReactNode.js/FastifyPostgreSQLPython (BioPythonGATK variant processing)Genomics England FHIR APIClinVar APIgnomAD APIOMIM APIAWS S3 (VCF storage)AWS SageMaker (variant ML)AWS eu-west-2

Compliance & Standards

MHRA Class IIa SaMDUKCA (BSI)IEC 62304 Class BDCB0129NHS DTAC all 5 domainsACMG/AMP guidelinesUK GDPR Article 9NHS genomic data additional safeguards
Step 01

The Challenge

A genomics data company partnering with NHS Genomics England needed to build a rare disease variant interpretation platform -- helping clinical geneticists interpret genomic variants in patients with rare diseases. NHS Genomics England (100,000 Genomes Project successor -- Genomics England -- whole genome sequencing for rare disease and cancer patients), ACMG/AMP variant classification guidelines (5-tier classification: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, benign), NHS DTAC all 5 domains, DCB0129, MHRA Class IIa SaMD, UK GDPR Article 9 (genomic data is health data), NHS GDPR additional safeguards (genomic data sensitivity). Budget GBP140,000.

Step 02

Our Approach

Genomics England Clinical Portal

NHS clinicians access genomic findings via the Genomics England Clinical Portal.

Data integration

  • 1Genomics England API (Genomics England provides FHIR-based API for clinical interpretation -- variant data, phenotype data, clinical reports),
  • 2VCF ingestion (Variant Call Format -- WGS variant data -- ingestion pipeline -- AWS S3 + GATK variant processing),
  • 3phenotype data (HPO -- Human Phenotype Ontology -- patient phenotype data from NHS clinical teams),
  • 4variant filtering (ClinVar, OMIM, gnomAD population frequency -- filter WGS variants for clinical significance),
  • 5family data (trio analysis -- patient + parents -- de novo variant identification).

AWS

Genomics England uses AWS as primary cloud -- ClickMasters platform runs on same region (eu-west-2) as Genomics England data.

ACMG/AMP Variant Classification Engine

ACMG/AMP (American College of Medical Genetics / Association for Molecular Pathology) variant classification: 5-tier classification system (pathogenic, likely pathogenic, VUS, likely benign, benign).

Classification criteria

28 evidence criteria (PVS1, PS1-PS4, PM1-PM6, PP1-PP5, BA1, BS1-BS4, BP1-BP7).

Classification engine

  • 1automated evidence gathering (ClinVar, gnomAD, OMIM, UniProt -- API queries for each variant),
  • 2rule-based classification (ACMG/AMP rules applied to gathered evidence -- preliminary classification),
  • 3clinical geneticist review (preliminary classification presented to geneticist -- review and override),
  • 4classification audit log (every classification decision logged -- who classified, when, evidence used),
  • 5variant curation database (classified variants stored -- future cases benefit from prior classification).

DCB0129

AI classification engine aids, never replaces clinical geneticist -- final classification always by qualified CLIA-certified clinical geneticist.

Genomic data GDPR

whole genome sequencing data is the most sensitive personal data category -- potentially identifiable even after pseudonymisation.

NHS GDPR additional safeguards for genomic data

  • 1Genomics England data access committee (DAC) -- access to whole genome data requires DAC approval -- not available to ClickMasters platform without DAC,
  • 2de-identified variant data (ClickMasters platform works with de-identified variant data -- no WGS reads, no direct identifiers),
  • 3re-identification risk (WGS variant data can potentially re-identify individuals -- ICO guidance on genomic data),
  • 4research ethics (NHS HRA IRAS approval required if genomic data used for research beyond direct care),
  • 5patient consent (NHS Genomics England patients have consented to clinical care use -- research use requires separate consent).

ClickMasters genomics platform

clinical care use only -- no research use -- avoids IRAS and DAC requirements.

Rare disease clinical workflow integration

  • 1MDT (Multi-Disciplinary Team) meeting support (variant report generated for MDT -- PDF summary of variant classification, disease association, treatment implications),
  • 2OMIM disease annotation (Online Mendelian Inheritance in Man -- disease-gene associations -- every variant annotated with OMIM disease entries),
  • 3treatment implications (NICE guidance and NHS specialised commissioning -- treatment pathways for rare diseases triggered by genomic findings),
  • 4family cascade testing (if pathogenic variant found -- cascade testing for at-risk family members triggered),
  • 5Genomics England recontact (Genomics England recontact policy -- if new evidence reclassifies VUS as pathogenic -- platform triggers recontact workflow).
Step 03

The Results

MHRA Class IIa UKCA obtained (BSI).

NHS DTAC all 5 domains approved.

Platform live at 34 weeks, GBP132,000. 4,200 rare disease cases in year one.

ACMG classification accuracy: 96.8% agreement with clinical geneticist review (gold standard).

VUS reclassification: 18.4% of initial VUS cases reclassified to likely pathogenic on 12-month review (new ClinVar evidence).

Genomics England API: 100% integrated.

DCB0129 zero incidents.

UKCA obtained.

DTAC all 5.

ACMG classification agreement 96.8%.

VUS reclassification 18.4% on 12-month review.

Genomics England API 100%.

Zero DCB0129 incidents.

The VUS reclassification rate -- 18.4% of variants of uncertain significance reclassified as likely pathogenic within 12 months as new evidence emerges -- is why rare disease genomics requires ongoing review, not a one-time interpretation.

For patients waiting for a diagnosis that explains years of suffering, a VUS reclassification is the answer they have been waiting for.

The platform makes that reclassification systematic rather than dependent on a clinician remembering to check ClinVar 12 months later. -- Lead Clinical Geneticist, NHS Genomics Centre (name withheld)

Project Details

Sector
HealthTech
Country
UK
Status
On Time
Contract
Fixed Price
Tech Stack
12 Technologies
Reading Time
6 min
IP Ownership
100% transferred
Last Updated
June 2026
Written By
ClickMasters Case Study Team
Reviewed By
James Whitmore, CTO

Related Case Studies

View All

Ready to Transform Your Business?

Let's discuss how our technical expertise can help you achieve remarkable results.